Cargando…
Quality of Life Differences for Primary Immunodeficiency Patients on Home SCIG versus IVIG
BACKGROUND: Patients with primary immunodeficiency disease (PIDD) and antibody deficiency require lifelong immunoglobulin replacement therapy. While both subcutaneous immunoglobulin (SCIG) and intravenous immunoglobulin (IVIG) replacement therapy are effective in preventing infection, patients with...
Autores principales: | Anterasian, Christine, Duong, Richard, Gruenemeier, Peg, Ernst, Carol, Kitsen, Jessica, Geng, Bob |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6863943/ https://www.ncbi.nlm.nih.gov/pubmed/31673923 http://dx.doi.org/10.1007/s10875-019-00705-5 |
Ejemplares similares
-
SCIg vs. IVIg: let’s give patients the choice!
por: Samaan, Kathryn K, et al.
Publicado: (2014) -
Implications to payers of switch from hospital-based intravenous immunoglobulin (IVIg) to home-based subcutaneous immunoglobulin (SCIg) therapy in patients with primary immunodeficiencies (PID) and secondary immunodeficiencies (SID) in Canada
por: Gerth, William C, et al.
Publicado: (2014) -
Individualizing Therapy in CIDP: A Mini-Review Comparing the Pharmacokinetics of Ig With SCIg and IVIg
por: Beydoun, Said R., et al.
Publicado: (2021) -
SCIG administration: A promising and patient convenient alternative for those receiving long-term IVIG
por: Hassini, Slim, et al.
Publicado: (2022) -
Impact of IVIG vs. SCIG on IgG trough level and infection incidence in primary immunodeficiency diseases: A systematic review and meta-analysis of clinical studies()
por: Shrestha, Pragya, et al.
Publicado: (2019)